Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 PB Ratio is 4.14 as of Jul. 17, 2026, which is 32% below its 10-year median of 6.05. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Pharma Aids ranks worse than 75.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), Pharma Aids's share price is BDT644.70. Pharma Aids's Book Value per Share for the quarter that ended in Mar. 2026 was BDT155.55. Hence, Pharma Aids's PB Ratio of today is 4.14.
The historical rank and industry rank for Pharma Aids's PB Ratio or its related term are showing as below:
DHA:PHARMAID'
s PB Ratio Range Over the Past 10 Years
Min: 3.21 Med: 6.05 Max: 12.24
Current: 4.14
During the past 13 years, Pharma Aids's highest PB Ratio was 12.24. The lowest was 3.21. And the median was 6.05.
DHA:PHARMAID's PB Ratio is ranked worse than 75.35% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs DHA:PHARMAID: 4.14
During the past 12 months, Pharma Aids's average Book Value Per Share Growth Rate was 16.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharma Aids was 18.60% per year. The lowest was 3.40% per year. And the median was 13.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pharma Aids PB Ratio Related Terms
Pharma Aids PB Ratio Historical Data
* Premium members only.
The historical data trend for Pharma Aids's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pharma Aids's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Pharma Aids's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pharma Aids (DHA:PHARMAID) has a PB Ratio of 4.14 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharma Aids and its competitors. This is 32% below median its historical median of 6.05. Over the past decade, Pharma Aids' PB Ratio has ranged from 3.21 to 12.24. According to the industry distribution chart, Pharma Aids ranks #593 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 75.3%.
Is Pharma Aids' PB Ratio too high?
Pharma Aids' current PB Ratio of 4.14 is 32% below median its 10-year median of 6.05. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 12.24. The Medical Devices & Instruments industry median PB Ratio is 2.05. Pharma Aids' value of 4.14 is 102% above this industry median. Based on the distribution chart, Pharma Aids ranks #593 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #593 out of 787 companies for PB Ratio. This places Pharma Aids in the lower half of its industry. The industry median PB Ratio is 2.05. Pharma Aids' value of 4.14 is 102% above this benchmark. Historically, Pharma Aids' own PB Ratio has ranged from 3.21 to 12.24 over the past decade. While the company's 10-year median is 6.05 vs. the industry median of 2.05, Pharma Aids has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current PB Ratio of 4.14 is 102% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current PB Ratio is 4.14, which is 32% below median its own 10-year median of 6.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current PB Ratio is 4.14, which is 32% below median its 10-year median of 6.05 and 102% above the Medical Devices & Instruments industry median of 2.05. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current PB Ratio is 4.14 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
PB Ratio: 4.14 (32% below median its 10-year median of 6.05)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
Industry Position: 102% above the Medical Devices & Instruments median (#593 of 787)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
